Kathleen T. Brady, MD, PhD
Dr. Brady has served as the Director and PI of the MUSC SCOR for the past nine years.  She is a Distinguished University Professor, psychiatrist and pharmacologist with a lengthy record of federally-funded clinical and translational research and considerable experience in teaching and research mentoring.  She has achieved national and international prominence for her research in the area of psychiatric comorbidity and addictions, and has over 300 scientific publications in this area.  Dr. Brady is also the PI for the NIH-sponsored Clinical Trials Network (CTN), which was initially funded in 2000 and funded again through competitive renewals in 2005 and 2010.  Dr. Brady serves as the Program Director of the MUSC General Clinical Research Center (GCRC) and Associate Dean for Clinical Research in the College of Medicine at MUSC.  In 2009, she led a successful application for a CTSA to form the South Carolina Clinical and Translational Research Institute (SCTR), which she now directs.  This position has enhanced her administrative experience, widened her research perspective and places her in an ideal position to continue to improve the visibility and prioritization of research in women’s health on the MUSC campus.

Ronald E. See, PhD
Dr. See has been a full Professor in the Department of Neurosciences and Department of Psychiatry at MUSC since 1999.  He played a pivotal leadership role in the establishment of the MUSC Neurosciences program and several addiction research initiatives at MUSC.  Dr. See has published more than 140 scientific papers and reviews, has made numerous national and international scientific presentations, served in a variety of capacities in national committees and organizations, and has been continuously funded by NIH since 1991.  In addition to his extensive work in animal models of addiction and relapse, he has developed a strong focus on translational research, including experience in clinical settings.  He previously directed a schizophrenia treatment study and served as a co-investigator in several recent clinical cue and stress reactivity studies.  Some of the current research in his laboratory is focused towards preclinical testing of pharmacotherapies for drug dependence, including compounds being assessed by Dr. Brady and colleagues.  Working closely with Dr. Brady, Dr. See has developed his studies using animal models of relapse in parallel with the human clinical laboratory to study cue, stress, and drug reactivity following chronic self-administration of drugs of abuse.  Dr. See is also a Core Director in the Neurobiology of Addiction Research Center at MUSC and a co-investigator in the MUSC Alcohol Research Center.  He has an extensive record of mentoring trainees in research activities, and over the last 25 years, he has served as a mentor for a number of undergraduate and pre-doctoral students, postdoctoral fellows, and junior faculty.

The scientific advisory board provides for scientific quality control, direction and interchange. Members of the scientific advisory board visit MUSC for a full day to meet with SCOR investigators and advise on programmatic and scientific issues. During these visits, the monthly SCOR meetings are used as a time for feedback and informal interactions between advisory board members and the MUSC SCOR team. Particular attention is given to areas of overlap and potential collaborations not yet realized. Board members also advise on issues concerning administration, outreach, and educational activities related to the SCOR. Finally, they meet with the SCOR Co-Directors in closed session to provide feedback.

Advisory board members are often invited for Grand Rounds and/or the Addiction Seminar series. These visits will be organized as described above with both individual consultation, a group meeting with the SCOR team, and individual meetings with the Co-PI’s. The advisory board members bring a unique blend of skills, expertise and perspective which help to strengthen the interdisciplinary and translational science and solidify the cohesion of the SCOR research team.

Shelley Greenfield, M.D., MPH 
Harvard University, Department of Psychiatry

Peter Kalivas, Ph.D.
Medical University of South Carolina, Department of Neurosciences

Edward D. Levin, Ph.D.
Duke University, Department of Psychiatry and Behavioral Sciences  

Carrie Randall, Ph.D.
Medical University of South Carolina, Department of Psychiatry